TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Trial of Patients With Complex Regional Pain Syndrome Comparing Graded Motor Imagery and Desensitization Versus Simple Desensitization and Changes in Resting-State Connectivity of Cerebral Networks Before and After Treatment.
Brief Summary: The intention of this trial is to investigate whether combined Graded Motor Imagery (GMI) and Desensitization (D) among patients with CRPS is clinically more effective than only D and to study changes in connectivity in the Default Mode Network before and after treatment.


Options:
A: Percentage of Participants Who Have a >= 30% Reduction (Improvement) in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score From Baseline to the Last Assessment (Day 0, Week 12)
B: Onset meaningful pain reduction
C: Pain intensity (between the first visit and three months after the beginning of the strategy.)
D: Group difference in pain intensity (6 weeks after baseline); Change from baseline in intra-network connectivity in the Default Mode Network (6 months after baseline)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)
Brief Summary: A multicenter, prospective, controlled, randomized (moderate hypothermia 33°C≤ T°C ≤34°C) during 24 hours ± 1h versus normothermia (36°C≤ T°C ≤37°C), comparative open trial will be conducted on two parallel groups of patients with cardiogenic shock treated with VA-ECMO.

The HYPO-ECMO trial will test the hypothesis that moderate hypothermia (temperature between 33°C≤ T°C ≤34°C) associated with VA-ECMO support results in a reduction in 30-day mortality in comparison with the normothermia group (36°C≤ T°C ≤37°C).


Options:
A: All cause mortality on day 60 following randomization (60 days)
B: Composite endpoint of survival with good neurological outcome (CPC 1-2). (6 months)
C: All-cause Mortality (Day 30)
D: Development of ARDS (28 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial
Brief Summary: endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).


Options:
A: Proportion of Treatment Failure (Unfavorable Outcome), Defined as Bacteriologic Failure or Relapse or Clinical Failure (Derived) Through Follow-up Until 6 Months After the End of Treatment. (6 Months post End of Treatment)
B: TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Modified Intent to Treat [MITT] Population) (Twelve months after treatment assignment); TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Assessable Population) (Twelve months after treatment assignment); Percentage Participants With Grade 3 or Higher Adverse Events During Study Drug Treatment in Control Regimen (Regimen 1 2HRZE/4HR) Compared to Experimental Regimens, Regimen 3 (2HPZM/2HPM) and Regimen 2 (2HPZ/2HP) (Safety Analysis Population) (Four months and up to 14 days after last does of after study treatment (Regimen 2 and 3) or Six months and up to 14 days after last does of after study treatment (Regimen 1))
C: Validation of Deeplex test (4 years); Validation of GeneXpert 2nd line (4 years); Validation of MolBio TrueNat for INH, FQ and BDQ (4 years); Validation of FDA microscopy (4 years); Validation of GeneXpert Ct value (4 years)
D: Week 73 Efficacy (Week 73 after randomization)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: CO-OPerative Training For Stroke Rehabilitation: A Phase II Trial Examining Meta-Cognitive Strategy Training in Acute Stroke Rehabilitation
Brief Summary: Cognitive impairments occur frequently after stroke, and are associated with significant long-term activities of daily living (ADL) disability and poor quality of life. This research study will undertake an innovative approach addressing cognitive impairments, by examining a new patient-centered functionally-relevant rehabilitation intervention that teaches individuals with cognitive impairments to manage their deficits to reduce ADL disability.


Options:
A: Patient Participation (12 and 36 weeks)
B: Social Functioning: Total Social Behavior (6 weeks)
C: Difference in Independence With Activities of Daily Living (Functional Independence Measure) Between Groups Over Time (Baseline, rehabilitation discharge, month 3, month 6)
D: Functionality in Activities of Daily Living (Changes in Scores Approach) (Baseline, 6 months and 12 months); Quality of Life (Changes in Scores Approach) (Baseline, 6 months and 12 months); Quality of Life (Clinically Significance Approach) (Baseline, 6 months and 12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Do Smartphones Increase Linkage to and Retention in Care in Newly Diagnosed HIV-positive Patients in Johannesburg, South Africa: A Multisite Randomised Controlled Trial
Brief Summary: This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained in care, and engage with educational materials purposefully developed to explain their results. Message prompts will also be used to alert patients that their results are ready and provide information on how to link to care, and assistance to re-link to care if they fall out of the health system for any reason. Prompts will be sent to patients to remind health care workers if they are due for repeat laboratory monitoring. The primary endpoint is linkage to care (a HIV-related laboratory test) at 6 months. The control group received standard of care.


Options:
A: Adherence to PrEP (Baseline to Week 48)
B: Use of long acting and reversible contraceptive at 4 months (4 months)
C: Linkage to HIV Care (Indicated by a HIV-related Laboratory Blood Test Within 8 Months) (Recruitment +8 months)
D: Differences in the Screen IVF questionaire between the intervention groups (through study completion, an average of 2 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Do Smartphones Increase Linkage to and Retention in Care in Newly Diagnosed HIV-positive Patients in Johannesburg, South Africa: A Multisite Randomised Controlled Trial
Brief Summary: This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained in care, and engage with educational materials purposefully developed to explain their results. Message prompts will also be used to alert patients that their results are ready and provide information on how to link to care, and assistance to re-link to care if they fall out of the health system for any reason. Prompts will be sent to patients to remind health care workers if they are due for repeat laboratory monitoring. The primary endpoint is linkage to care (a HIV-related laboratory test) at 6 months. The control group received standard of care.


Options:
A: Plasma HIV-1 viral load (six months)
B: ANC (Assess the recommend number of ANC (4 ANC) coverage 18 months after intervention); PNC (Assess the recommend number of PNC (3 ANC) coverage 18 months after intervention); Contraceptive prevalence rate (CPR) (Assess the Contraceptive prevalence rate (CPR) at the end of intervention of 18 months.); EPI coverage (Assess the EPI vaccination coverage at the end of the intervention of 18 months)
C: Linkage to HIV Care (Indicated by a HIV-related Laboratory Blood Test Within 8 Months) (Recruitment +8 months)
D: Self-reported completion of a full course of PEP medications and receipt of a final HIV test result from their nPEP provider 12 weeks after the index exposure (12 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Do Smartphones Increase Linkage to and Retention in Care in Newly Diagnosed HIV-positive Patients in Johannesburg, South Africa: A Multisite Randomised Controlled Trial
Brief Summary: This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained in care, and engage with educational materials purposefully developed to explain their results. Message prompts will also be used to alert patients that their results are ready and provide information on how to link to care, and assistance to re-link to care if they fall out of the health system for any reason. Prompts will be sent to patients to remind health care workers if they are due for repeat laboratory monitoring. The primary endpoint is linkage to care (a HIV-related laboratory test) at 6 months. The control group received standard of care.


Options:
A: Change in Exclusive Breastfeeding Rate (2 weeks after birth); Change in Exclusive Breastfeeding Rate (3 months after birth); Change in Exclusive Breastfeeding Rate (6 months after birth)
B: Unprotected sex, no contraceptive (6-week post-baseline (in the past 6 weeks)); Unprotected sex, no highly effective contraceptive (6-week post-baseline (in the past 6 weeks))
C: Clinic attendance for pills pick up (six months.)
D: Linkage to HIV Care (Indicated by a HIV-related Laboratory Blood Test Within 8 Months) (Recruitment +8 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Retention in care with viral suppression (48 weeks after HIV testing)
B: Treatment time (Up to 8 weeks)
C: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)
D: Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay positive and/or MGIT culture positive for M.tuberculosis. (week 0); Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay negative and/or MGIT culture negative for M.tuberculosis. (week 0); Proportion of clinically diagnosed non-TB participants with CRISPR-based test MTB positive in sputum/BALF. (week 0)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Retention in care with viral suppression (48 weeks after HIV testing)
B: Treatment time (Up to 8 weeks)
C: Time to TB treatment initiation (8 weeks follow up)
D: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay (Day 1)
B: Proportion of Treatment Failure (Unfavorable Outcome), Defined as Bacteriologic Failure or Relapse or Clinical Failure (Derived) Through Follow-up Until 6 Months After the End of Treatment. (6 Months post End of Treatment)
C: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)
D: Treatment time (Up to 8 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Survival of newly-diagnosed HIV-infected patients at 1 year (4 years)
B: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)
C: Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay (Day 1)
D: increase TB case detection (6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)
B: Tuberculosis diagnostic algorithm (3 years)
C: Retention in care with viral suppression (48 weeks after HIV testing)
D: Treatment time (Up to 8 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Retention in care with viral suppression (48 weeks after HIV testing)
B: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)
C: Time to TB treatment initiation (8 weeks follow up)
D: Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay (Day 1)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Treatment time (Up to 8 weeks)
B: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases (2 months after enrollment)
C: Retention in care with viral suppression (48 weeks after HIV testing)
D: Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay positive and/or MGIT culture positive for M.tuberculosis. (week 0); Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay negative and/or MGIT culture negative for M.tuberculosis. (week 0); Proportion of clinically diagnosed non-TB participants with CRISPR-based test MTB positive in sputum/BALF. (week 0)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparison of Standard Catheter Directed Thrombolysis vs. Ultrasound Assisted Thrombolysis for Patients With Acute Submassive Pulmonary Embolism
Brief Summary: The study will compare standard catheter directed thrombolysis to ultrasound accelerated thrombolysis for the treatment of acute submassive pulmonary embolism (PE). The study population will include patients eligible for catheter directed thrombolysis (CDT) for submassive PE. Subjects will be randomized to, either, standard catheter-directed thrombolysis or ultrasound-accelerated thrombolysis (USAT).


Options:
A: PE thrombus load reduction (CT obstruction index) from baseline to the termination of lysis (48 hours)
B: Right Ventricle/Left Ventricle (RV:LV) Ratio (from baseline to 48 hours); Major Adverse Event Rate (within 48 hours)
C: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) (Between 6 and 24 months after randomization)
D: Number of Patients With Cardiogenic Shock or Respiratory Failure From Pulmonary Embolism and Number of Patietnts With Major Hemorrhage (1,2,3,4, and 5 days); Number With Functional Cardiopulmonary Limitations Assessed With a Composite Measurement (Six Minute Walk Distance, Right Ventricular Function and Quality of Life Score on the SF-36) (90 days); Number With Recurrent Venous Thromboembolism and/or Severe Post-phlebitic Syndrome (90 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Impact of C-reactive Protein Testing on Antibiotic Prescription in Febrile Patients Attending Primary Care in Low-resource Settings
Brief Summary: PRIMARY OBJECTIVE To assess the impact of C-reactive protein (CRP) Point-of-care (POC) testing on health care worker prescribing behaviour in patients presenting to primary healthcare centres with an acute fever or recent history of fever.

SECONDARY OBJECTIVES To assess the impact of CRP testing on clinical outcomes within the 14 days of follow-up.

To assess the correlation between CRP results and clinical outcomes on the day 5 of the enrolment.

To estimate the impact of CRP testing on antibiotic consumption after first consultation.

To explore the attitudes of health centre staff towards the POC CRP test. To identify the prevalence of key pathogens in febrile patients in these settings.

To validate the ability of CRP to discriminate between viral and bacterial pathogens in a subset of patients with a microbiologically confirmed diagnosis.


Options:
A: duration of antibiotic therapy expressed in days of therapy (Between Day 1 and Day 30)
B: Antibiotic prescription rate (24 hours)
C: The proportion of recruited patients prescribed an antibiotic (6 Days)
D: days with significant impairment due to acute respiratory tract infection (14 to 28 days after infection)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Does the Addition of Dexamethasone to a Local Infiltration Analgesia Mixture Improve Functional Outcomes Following Total Joint Arthroplasty?
Brief Summary: This study will evaluate if the addition of dexamethasone to a local infiltration analgesia mixture will improve functional outcomes following total hip and knee arthroplasty.


Options:
A: Painscore during mobilization (2-24 hours after extubation time.)
B: Cumulative systemic opioid consumption measured as oral morphine mg equivalents at 24 hours postoperatively (3 days - post operative)
C: Change in incidence of postoperative nausea and vomiting (The incidence was recorded at 1 hour as a baseline and changing incidences from baseline were recorded at 2 hours, 4 hours, and 24 hours.)
D: Cumulative usage of morphine 0-48 hours postoperatively (0-48 hours postoperatively)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Double-blind Randomized Controlled Clinical Trial of 3 Days of Amoxicillin Disperable Tablet (DT) Versus Placebo for Fast Breathing Childhood Pneumonia Among Children 2-59 Months of Age Presenting to Kamuzu Central Hospital in Lilongwe, Malawi
Brief Summary: The purpose of this study to assess the effectiveness of no antibiotic treatment for fast breathing, community-acquired childhood pneumonia in a malaria-endemic region of Malawi.


Options:
A: Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization (From study Day 0 through study Day 150)
B: Cumulative incidence of recurrent wheezing confirmed by physicians (two years)
C: Proportion of children failing treatment (4 days)
D: Clinical Cure: Respiratory rate below age specific cut-off (<50 bpm in infants <12 months and <40 bpm in 12 - 59 months of age).

Answer: C